CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective faithfully but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire interview that I came away with an inadequate opinion of the business.

Irony of irony, my poor impression of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of this technology and also associated intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 zillion) and also the first new drug program endorsement ($5 million), as well as royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and numerous indications, it’s this single remedy in addition to a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an energetic company with diverse interests albeit centered on leronlimab, several illness types, multiple presentations in addition to multiple publications.

Could all this be smoke and mirrors? That’s a question I have been asking myself from the really beginning of the interest of mine in this business. Judging by way of the multiples of a huge number of various remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some may say cult stock. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News